Ellis et al., 201911 Iraqi Cancer Registry. Ministry Of Health, Iraqi Cancer Board, Baghdad, Iraq; 2011 https://moh.gov.iq/upload/upfile/ar/273.pdf
https://moh.gov.iq/upload/upfile/ar/273....
|
Comparison SEER-Medicare |
482 |
Adjuvant/neoadjuvant plus surgery |
24 month |
2.5%/3.4% complete response |
Treated with CRT-only were less likely to receive surveillance than those treated with conventional treatment |
8 |
Chapman et al., 201922 Iraqi Cancer Registry. Annual Report. Iraqi Cancer Registry Board, Ministry Of Health and Environment. Baghdad, Iraq; 2015.
|
Retrospective cohort study |
388 |
Neoadjuvant, and TMR |
9 years |
pCR rate of 25% and overall recurrence rate of 14.9% |
Short course radiation with neoadjuvant multi-agent chemotherapy is at least as effective as long-course CRT |
7 |
Quezada-Diaz et al., 201933 Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2018;68:394-424.
|
Retrospective review |
176 |
Adjuvant, neoadjuvant, and surgery |
6 years |
- |
The trimodality treatment does not seem to impair bowel function |
7 |
Spiegel et al., 201844 NCCN. Clinical Practice Guidelines in Oncology. Rectal Cancer Version.2; 2019 www.nccn.org. www.nccn.org...
|
Veterans Health Administration analysis |
649 |
Adjuvant, neoadjuvant, and TMR |
66 months |
Improve both OS and DFS |
There was no improvement in OS or DFS with the addition of a multi-agent over single-agent chemotherapy |
8 |
Mancini et al., 201755 Alberts SR, Grothy A. In: Casciato DA, Territo MC, editors. Manual of Clinical Oncology: Colorectal cancer. 7th ed. USA: Lippincott Williams & Wilkins, a Wolters Kluwer business; 2012. p. 239–58.
|
Multiple correspondence analysis |
174 |
Neoadjuvant plus surgery |
10 years |
13.2% complete response |
Neoadjuvant CRT and radical surgery enrich the prognostic profile of patients |
8 |
Franke et al., 201766 Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007;25:4379-86.
|
Systematic review |
- |
Neoadjuvant plus surgery |
5 years |
Reduced local recurrence rates |
Outline the pragmatic opportunities for future investigation into questions of efficacy, safety, and ultimate improvements |
7 |
Dossa et al., 201777 Mohiuddin M, Willett CG, et al. In: Halperin EC, Perez CA, Brady LW, editors. Principles and practice of radiation oncology: Colon and Rectum, 2015, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2015. p. 1366–82.
|
Systematic review and meta-analysis |
867 |
Neoadjuvant plus watch-and-wait |
12-68 months |
- |
Most patients treated by watch-and-wait avoid radical surgery and of those who have regrowth almost all have salvage therapy |
7 |
Kimberly et al., 201788 Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184-90.
|
Phase II randomized trial |
93 |
Adjuvant and neoadjuvant plus surgery |
4 years |
All patients had resolution of bleeding and improvement of obstructive symptoms, with no complications requiring surgical intervention. |
TRIAL seems to be a well-tolerated alternative to the current standard treatment sequence. |
6 |
Rodel et al., 201699 Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926-33.
|
Meta-analysis |
- |
Preoperative/postoperative plus TMR |
- |
Encouraging pCR rates but increased surgical complications |
The benefit role of induction and consolidation chemotherapy before or after CRT. The minimal or omitted surgery following complete response to CRT The omission of radiotherapy for selected patients with response to neoadjuvant chemotherapy. |
7 |